"EMA Expands Investigation into GLP-1 Receptor Agonists and Suicidal Thoughts"
TL;DR
The European Medicines Agency (EMA) is conducting a review of GLP-1 receptor agonists, including Ozempic, Saxenda, and Wegovy, due to reports of suicidal thoughts and self-injury. The review was triggered by the Icelandic medicines agency and is analyzing approximately 150 cases. It is unclear whether these cases are directly linked to the medications or other factors. The review is expected to conclude in November 2023. Patients and healthcare professionals are advised to use these medications according to approved guidelines and report any suspected side effects.
- EMA statement on ongoing review of GLP-1 receptor agonists | European Medicines Agency European Medicines Agency |
- Regulators examine possible link between Ozempic, suicidal thoughts l GMA Good Morning America
- Ozempic diabetes and weight loss medication under investigation after a few reports of suicidal thoughts Yahoo News
- EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs CNBC
- EU regulations expand investigation into link between Ozempic, suicidal thoughts CBS Philly
Want the full story? Read the original reporting
Read on European Medicines Agency |